Suscribirse

Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study - 04/02/25

Doi : 10.1016/S1470-2045(24)00678-8 
Fabio Y Moraes, MD PhD a, c, * , Andre G Gouveia, MD MBA d, *, Vanessa Freitas Bratti, MD MPH b, Edward C Dee, MD e, Juliana Fernandes Pavoni, PhD f, Laura M Carson, MPH a, Cecília Félix Penido Mendes de Sousa, MD g, Richard Sullivan, MD PhD h, Gustavo Nader Marta, MD PhD i, Wilma M Hopman, MA b, Christopher M Booth, MD a, c, Ajay Aggarwal, MD PhD j, k, Ahmedin Jemal, DVM PhD l, Timothy P Hanna, MD PhD a, c, Brooke E Wilson, MD MSc a, c, , Gustavo Arruda Viani, MD PhD m,
a Department of Oncology, Queen’s University, Kingston, ON, Canada 
b Department of Public Health Sciences, Queen’s University, Kingston, ON, Canada 
c Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen’s University, Kingston, ON, Canada 
d Division of Radiation Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada 
e Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
f Faculty of Philosophy, Languages and Human Sciences, University of São Paulo, São Paulo, Brazil 
g Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 
h Institute of Cancer Policy, Global Oncology Group, King’s College London, London, UK 
i Department of Oncology, Division of Radiation Oncology, Hospital Sirio Libanês, São Paulo, Brazil 
j Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK 
k Department of Clinical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK 
l Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA 
m Ribeirão Preto Medical School, Department of Medical Imaging, Haematology and Oncology, University of São Paulo, São Paulo, Brazil 

* Correspondence to: Dr Fabio Y Moraes, Department of Oncology, Queen’s University, Kingston K7L 5P9, ON, Canada Department of Oncology Queen’s University Kingston ON K7L 5P9 Canada

Summary

Background

The Linear Accelerator Shortage Index (LSI) is a practical tool for prioritising the deployment of linear accelerators (LINACs) in various regions within a country. The LSI reflects the ratio of LINAC demand to current availability. The aim of this study was to use the LSI to predict global LINAC needs and classify countries according to the degree of radiotherapy shortage (LINAC shortage grade).

Methods

In this cross-sectional, population-based study of globally representative, country-level data, we sourced regional LINAC distribution, numbers of radiotherapy centres, and cancer incidence data for 181 countries from the Directory of Radiotherapy Centers and Global Cancer Observatory 2022 databases. Current gross domestic product and gross national income per capita in US dollars were obtained from the World Bank. We calculated an LSI for each country to assess the relative demand and supply of radiotherapy by dividing LINAC use by 450 and multiplying by 100. An LSI of 100 or less indicates no shortage (450 or fewer patients per LINAC), whereas an LSI greater than 100 signals a shortage, with higher values indicating more severe deficits. We categorised countries by LINAC shortage grade: grade 0 (LSI ≤100, no shortage), grade 1 (LSI 101–130, low need), grade 2 (LSI 131–300, high need), grade 3 (LSI >300, excessive need), or grade 4 (no existing LINACs). We estimated LINAC requirements until 2045 using the LSI and Global Cancer Observatory data. We determined future investment costs according to the LSI for each country.

Findings

As of the data cutoff on Sept 15, 2024, the global median LSI was 130 (IQR 96–319), suggesting a shortage of 30% in radiotherapy capacity. Significant disparities in median LSI were observed across income levels: low-income countries had a median LSI of 1523 (528–2247), lower-middle-income countries 399 (183–685), upper-middle-income countries 133 (104–198), and high-income countries 96 (83–127; p<0·0001). The distribution of countries across LINAC shortage grades was 40 (22%) of 181 as grade 0, 32 (18%) as grade 1, 35 (19%) as grade 2, 38 (21%) as grade 3, and 36 (20%) as grade 4 (no LINACs). Most LINAC shortage grade 4 countries were low income (12 [33%]) or lower-middle income (16 [44%]). The median number of new LINACs needed per country by 2045 was estimated at 6 (1–13) for grade 0, 21 (4–102) for grade 1, 22 (8–80) for grade 2, 52 (26–113) for grade 3, and three (2–14) for grade 4. To meet these demands, also including the replacement of obsolete devices, an estimated 30 470 LINACs will be needed by 2045. The median total investment required for new and replacement machines and radiotherapy centres to meet the 2045 demand is projected at US$162 million (49–369) for grade 0, $216 million (54–772) for grade 1, $143 million (64–580) for grade 2, $238 million (126–561) for grade 3, and $16 million (9–59) for grade 4. A significant change in LINAC shortage grade composition between 2020 and 2045 is predicted, with distribution of 40 (22%) versus seven (4%) for grade 0, 32 (18%) versus 23 (13%) for grade 1, 35 (19%) versus 63 (35%) for grade 2, 38 (21%) versus 52 (29%) for grade 3, and 38 (20%) versus 38 (20%) for grade 4 (p<0·0001).

Interpretation

The LSI and LINAC shortage grade systems are effective for evaluating, monitoring, and forecasting global LINAC needs. The LSI and LINAC shortage grade highlight the substantial disparities in radiotherapy availability and underscore the urgent need for investment in radiotherapy capacity building, particularly in many low-income and middle-income countries.

Funding

None.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2025  Elsevier Ltd. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 26 - N° 2

P. 239-248 - février 2025 Regresar al número
Artículo precedente Artículo precedente
  • Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
  • Dan-Yun Ruan, Fu-Rong Liu, Xiao-Li Wei, Su-Xia Luo, Zhi-Xiang Zhuang, Zhen-Ning Wang, Fu-Nan Liu, Yan-Qiao Zhang, Jian-Wei Yang, Zhen-Dong Chen, Yong-Sheng Wang, Jun-Ye Wang, Xiao-Hua Liang, Xiao-Jie Wu, Yu-Long Zheng, Jian Liu, Xi Shi, Rakesh Kumar, Wei Liu, Bo Chen, Dong-Sheng Zhang, Rui-Hua Xu
| Artículo siguiente Artículo siguiente
  • Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
  • Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Rebecca Kristeleit

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.